A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis

Trial Profile

A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs ASN 002 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Asana BioSciences
  • Most Recent Events

    • 19 Jul 2018 According to an Asana BioSciences media release, Dr. Robert Bissonnette is the President of Innovaderm Research, Montreal, Canada and a lead investigator for the ASN002 Phase 1b and Phase 2b RADIANT study.
    • 08 May 2018 According to an Asana BioSciences media release, efficacy and biomarker data from this study will be presented at the International Eczema Council (IEC) meeting and at the International Investigative Dermatology (IID) meeting.
    • 31 Jan 2018 According to an Asana BioSciences media release, data will be presented in the late-breaking session at the annual meeting of the American Association of Dermatology 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top